Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion

Melissa A Tran1, Raghavendra Gowda, Arati Sharma

  • 1Department of Pharmacology, The Pennsylvania State University, Hershey, Pennsylvania 17033, USA.

Cancer Research
|September 17, 2008
PubMed

Insights

This study introduces a novel nanoliposomal-ultrasound method to deliver siRNA targeting B-Raf and Akt3, effectively reducing melanoma development with minimal toxicity.

Area of Science:

  • Oncology
  • Biotechnology
  • Molecular Biology

Background:

  • Melanoma development involves B-Raf and Akt3 signaling pathways.
  • Specific mutations like T1799A in B-Raf ((V600E)B-Raf) and elevated Akt3 signaling are common in melanomas.
  • Targeted therapies are needed to inhibit these specific pathways with fewer side effects.

Purpose of the Study:

  • To develop a novel nanoliposomal-ultrasound delivery system for siRNA targeting (V600E)B-Raf and Akt3.
  • To evaluate the efficacy of this approach in reducing melanoma development in skin.
  • To assess the safety and systemic toxicity of the targeted delivery system.

Main Methods:

  • Utilized cationic nanoliposomes to encapsulate siRNA targeting (V600E)B-Raf or Akt3.
  • Employed low-frequency ultrasound for enhanced penetration of the nanoliposomal-siRNA complex into skin layers.
  • Administered the treatment to melanocytic tumors in laboratory or animal skin models.

Main Results:

  • Nanoliposomal siRNA delivery successfully targeted and reduced the expression of (V600E)B-Raf and Akt3 in melanoma cells.
  • Combined targeting of (V600E)B-Raf and Akt3 resulted in a significant, cooperative decrease of approximately 65% in melanoma.
  • The treatment exhibited negligible associated systemic toxicity.

Conclusions:

  • Cationic nanoliposomes combined with ultrasound offer an effective strategy for targeted siRNA delivery to melanoma.
  • This approach provides a promising therapeutic avenue for inhibiting early and invasive cutaneous melanomas.
  • The targeted inhibition of (V600E)B-Raf and Akt3 signaling pathways shows potential for melanoma treatment with improved safety profiles.